


Data Sheet

Product Name:	L-Eflornithine (monohydrochloride)
Cat. No.:	CS-0083703
CAS No.:	69955-42-6
Molecular Formula:	C ₆ H ₁₃ ClF ₂ N ₂ O ₂
Molecular Weight:	218.63
Target:	Parasite
Pathway:	Anti-infection
Solubility:	DMSO : 200 mg/mL (ultrasonic); H ₂ O : 50 mg/mL (ultrasonic)



BIOLOGICAL ACTIVITY:

L-Eflornithine monohydrochloride (L-DFMO monohydrochloride) is an enantiomer of Eflornithine. L-Eflornithine is an irreversible **ornithine decarboxylase (ODC)** inhibitor with a K_D of $1.3 \pm 0.3 \mu\text{M}$, and a K_{inact} of $0.15 \pm 0.03 \text{ min}^{-1}$ [¹]. IC₅₀ & Target: KD: $1.3 \pm 0.3 \mu\text{M}$ (Ornithine decarboxylase, ODC)[¹] *In Vitro*: Eflornithine (D/L-DFMO) is an inhibitor of ODC, the first enzyme in eukaryotic polyamine biosynthesis. Both enantiomers of Eflornithine (DFMO) irreversibly inactivate ODC. Both Eflornithine enantiomers (L-Eflornithine and D-Eflornithine) suppress ODC activity in a time- and concentration-dependent manner. The inhibitor dissociation constant (K_D) values for the formation of enzyme-inhibitor complexes are 28.3 ± 3.4 , 1.3 ± 0.3 and $2.2 \pm 0.4 \mu\text{M}$ respectively for D-Eflornithine, L-Eflornithine and Eflornithine. The inhibitor inactivation constants (K_{inact}) for the irreversible step were 0.25 ± 0.03 , 0.15 ± 0.03 and $0.15 \pm 0.03 \text{ min}^{-1}$ respectively for D-Eflornithine, L-Eflornithine and Eflornithine. Treatment of human colon tumour-derived HCT116 cells with either L-Eflornithine or D-Eflornithine decreases the cellular polyamine contents in a concentration-dependent manner[¹]. The enantiomers display different potencies in vitro, with the L-enantiomer having up to a 20-fold higher affinity for the target enzyme ornithine decarboxylase[²].

The L-Eflornithine also appears to be more potent in cultured *T.brucei gambiense* parasites[²].

In Vivo: The more potent L-Eflornithine is present at much lower concentrations in both plasma and cerebrospinal fluid (CSF) than those of the D-Eflornithine. The plasma concentrations of L-Eflornithine are on average 52% of the D-enantiomer concentrations. The typical oral clearances of L-Eflornithine and D-eflornithine are 17.4 and 8.23 liters/h, respectively[²].

References:

- [1]. Qu N, et al. Inhibition of human ornithine decarboxylase activity by enantiomers of difluoromethylornithine. *Biochem J.* 2003 Oct 15;375(Pt 2):465-70.
- [2]. Jansson-Löfmark R, et al. Enantiospecific reassessment of the pharmacokinetics and pharmacodynamics of oral eflornithine against late-stage *Trypanosoma brucei gambiense* sleeping sickness. *Antimicrob Agents Chemother.* 2015 Feb;59(2):1299-307.

CAIndexNames:

L-Ornithine, 2-(difluoromethyl)-, monohydrochloride (9CI)

SMILES:

N[C@](CCCN)(C(F)F)C(O)=O.Cl

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128

Fax: 888-484-5008

E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA